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Abstract: Studies in patients and chimpanzees that spontaneously clear Hepatitis C Virus 
(HCV) have demonstrated that natural immunity to the virus is induced during primary 
infections and that this immunity can be cross protective. These discoveries led to 
optimism regarding prophylactic HCV vaccines and a number of studies in the chimpanzee 
model have been performed, all of which resulted in modified infections after challenge but 
did not always prevent persistence of the virus. Therapeutic vaccine strategies have also 
been pursued in an effort to reduce the costs and side effects associated with anti-viral drug 
treatment. This review summarizes the studies performed thus far in both patients and 
chimpanzees for prophylactic and therapeutic vaccination, assesses the progress made and 
future perspectives. 
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1. Introduction 
Hepatitis C virus (HCV) is an enveloped virus with a single stranded, plus sense RNA genome. The 
RNA (~9.6 kb in length) consists of a ~341-base 5' non-translated region (NTR), a single open reading 
frame encoding all virus-specific proteins (~3011 amino acids), and a 3' NTR. Translation of the 
genome RNA is cap-independent and mediated by the 5' NTR which functions as an internal ribosome 
entry site. The resulting polyprotein is cleaved, both co- and post-translationally by host and viral 
proteases. The structural proteins, which include the core and the envelope glycoproteins (E1, E2) are 
located at the N-terminus; the nonstructural (NS) components are located in the carboxy terminus two 
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thirds and include p7, NS2-3 (a protease), NS3 (a serine protease and RNA helicase), NS4A, NS4B, 
NS5A and NS5B (an RNA-dependent RNA polymerase) [1,2].  
Transmission of HCV is typically by the parenteral route, but per mucosal transmission such as 
sexual and maternal infant transmission do occur. Persistent infections caused by HCV occur in   
70-80% of the acutely infected population, the majority of which will develop chronic hepatitis and 
will be at risk for cirrhosis, end-stage liver disease and/or hepatocellular carcinoma [3]. HCV is 
associated with 40-60% of chronic liver disease in the U.S. Of these patients, one third goes on to 
develop progressive fibrosis and cirrhosis [4] making hepatitis C the major disease leading to liver 
transplantation [3]. Hepatitis C is now the major cause of hepatocellular carcinoma (HCC) in Japan, 
having displaced hepatitis B and, according to the CDC, there are 8,000-10,000 deaths each year in the 
U.S. alone due to HCV-associated cirrhosis and cancer.  
Significant progress has been made in the therapy of chronic hepatitis C. Current therapies with 
pegylated IFN-α and Ribavirin clear HCV infection in approximately 50% of cases, but treatment 
remains very expensive, requires 6-12 months of therapy, and carries a significant risk of serious side 
effects [5-7]. Currently, there are about 25,000 new HCV infections each year in the U.S. alone, 
making the development of a prophylactic vaccine against this virus imperative. An immunologic 
approach to treatment is also sought to either replace or enhance drug treatment. Major benefits in 
expenses and logistics would be gained if it were possible to treat a chronic HCV patient with   
2-3 doses of a therapeutic vaccine as opposed to 6 to 12 months of combination IFN and drug therapy. 
In this review the current understanding of immune responses that are induced during primary and 
secondary infections with HCV and the efficacy of protective immune responses induced with 
prophylactic vaccine candidates in pre-clinical studies using chimpanzees will be discussed. The 
feasibility and progress of immunotherapeutic studies in humans and non-human primates designed to 
treat patients chronically infected with HCV will also be discussed. 
2. Genetic Diversity of HCV 
In general, during replication of RNA viruses errors are randomly introduced into the genome by 
the RNA-dependent RNA polymerase (RdRp) and, due to the lack of proof-reading function in these 
enzymes, remain uncorrected. Many of these misincorporations are lethal for the virus and go 
undetected, others are silent, leading to a change in the nucleotide sequence but maintaining the amino 
acid residue. A third type of mutation changes the amino acid sequence. These non-lethal mutations 
have either no effect on virulence or confer an advantage to the virus such that it can replicate more 
efficiently, evade the host immune response or develop drug resistance. Thus, variant RNA genomes 
or polypeptide sequences can evolve establishing, in the case of HCV, the co-existence of several 
closely related but distinct viruses within a single host, referred to as a quasispecies population. 
Nucleotide sequences of viral isolates have been studied extensively and six major genotypes 
(designated 1-6) have been defined, differing by 30-35% over the complete genome [8]. The greatest 
genetic variability is observed in the E1 and E2 glycoproteins and the NS5A region with higher 
sequence conservation observed in the NS3 and NS5B regions, the core gene and the 5’UTR [8]. 
Within each of the six major genotypes there exist more closely related subtypes (designated 1a, 1b, 2a, 
3a etc.) differing from each other by 20-25% at the nucleotide level [8]. An unusually high degree of Viruses 2009, 1                                       
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amino acid variation has been observed in the N terminus of the E2 protein [9,10]. This hypervariable 
region, referred to as HVR1, is located between aa 384-410 of the polyprotein (aa1-27 of E2). The 
HVR1 varies enormously both within any one isolate and between different genotypes [11,12]. 
Secondary structure predictions indicate the HVR1 of HCV is highly unstructured [13], which is 
consistent with a tolerance for the degree of sequence variation observed, and has been shown to be 
dispensable for replication and in vivo infection [14]. The HVR1 has also been shown to contain 
neutralizing antibody epitopes [15] and observations that specific antibody to this region changes 
during the course of chronic infections suggests that HVR1 is subject to immune pressure with the 
potential for escape mutants [13,16-18]. 
HCV sequences are continually evolving during an infection due to the error-prone NS5B RdRp, 
which generates an estimated 10
-5 mutations/nucleotide/replication [19], and the high production and 
clearance rate of the virus, estimated at 10
12 virions per day [20]. Immune escape has been shown 
directly and indirectly in a number of instances for natural infections in both T-cell [21-23] and B-cell 
[16,18,24] epitopes. Immune escape in CD4+ [25] and CD8+ [26] T-cell epitopes have also been 
shown in chimpanzees following failure of T-cell based vaccines, although immune escape from 
neutralizing antibody has not yet been demonstrated in vaccine studies. 
HCV genetic diversity poses problems for vaccine development from the perspective of target 
antigens and the potential for escape from the vaccine-induced immune response. The variation in 
virus isolates has led to suggestions that a vaccine would need to be tailored to all six genotypes to be 
effective. However, patient plasma samples and monoclonal antibodies have been identified that are 
capable of cross-neutralizing a number of different genotypes [27-30] suggesting an effective cross 
reactive vaccine targeting the envelope region could be designed. T-cell-based vaccines have also 
received a great deal of focus partly due to the role of T-cells in natural clearance (see Section 4 below) 
but also because these vaccines can target the more conserved regions of HCV. Both of these 
approaches for the development of prophylactic vaccines against HCV are discussed more fully in 
Section 5. 
3. HCV Kinetics During Primary and Secondary Infections 
In primary HCV infections acute hepatitis develops at ~8-14 weeks, when serum ALT levels 
increase and HCV-specific T-cells become detectable in the liver. The replication kinetics are 
characterized by a rapid (logarithmic) viral increase during the first 1-2 weeks, with a mean doubling 
time of ~0.5 days, after which the viral increase slows to a mean half-life of 7.5 days [31]. 
Concomitant with ALT elevations viral titers rapidly decline at ~8-14 weeks [31-33] at which point 
CD8
+ T-cell responses and increased intrahepatic IFN-γ expression can be detected [31,32,34,35], 
which is associated with T-cell mediated immune responses. Early studies on HCV infections in 
chimpanzees and humans demonstrated that individuals that had recovered from a primary infection 
with the virus could be reinfected with homologous or heterologous strains [36,37]. However, 
subsequent studies in humans and chimpanzees have demonstrated that although reinfection does 
occur the viral kinetics are very different with immediate control of viral replication and rapid 
clearance in the majority of cases [38-40], although persistent infections following prior clearance can 
occur [41]. These data support the argument that adaptive immune responses are induced during a Viruses 2009, 1                                       
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primary infection and that these responses can modify secondary infections and clear HCV more 
rapidly. Studies on viral kinetics have shown that the second infection is of short duration with a 
reduced viral titer in the blood and liver in comparison to the initial infection and reduced hepatic 
inflammation as indicated by alanine amino transferase levels (ALT) (Figure 1) [38,39]. Importantly, 
this level of protection also appears to be effective against other genotypes [42,43].  
Figure 1. Schematic representation of primary and secondary infections with hepatitis C 
virus. Viral RNA titers in the serum are shown in blue; serum alanine aminotransferase 
(ALT) levels indicative of hepatitis are shown as a black solid line; seroconversion to anti-
HCV antibodies as assessed by commercial assays is shown in red. 
 
4. Immune Correlates of Viral Clearance 
Both CD4+ and CD8+ T-cells have been shown to play a major role in clearance of HCV during 
primary and secondary infections with strong support for the involvement of immune responses to 
HCV NS3 in clearance of acute infection [44-49] (reviewed in [50]). After spontaneous recovery from 
HCV, resting HCV-specific memory T-cells can be detected in the peripheral blood of patients for 
decades, in many cases in the absence of detectable HCV antibodies [51]. HCV-specific cellular 
immune responses also persist in the liver, as demonstrated in recovered chimpanzees, and mediate 
protective immunity on reinfection [34,35,39,52,53]. The essential role of neutralizing antibody in 
controlling viral replication during primary or secondary infections is still unclear. Until the 
development of lentiviral/HCV pseudotype particle systems bearing the HCV envelope glycoproteins 
on the particle surface [54,55] the neutralizing ability of anti-envelope antibodies had been difficult to 
measure. More recently a cell culture system for HCV was developed using a genotype 2a virus 
[56,57] and although the 2a genotype virus remains the only genome able to robustly replicate and 
produce infectious virus in vitro this system has been used to generate chimeric viruses expressing the 
envelope proteins of all HCV genotypes [58-61]. Using these tools it has been shown that patients 
produce antibodies that neutralize infectivity in vitro and can cross neutralize a number of different 
genotypes [27,62]. High titers of neutralizing antibody are not produced until the chronic phase of the 
infection [27] and although the induction of neutralizing antibodies has in some cases been associated Viruses 2009, 1                                       
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with clearance of the virus [63-65], it appears such antibodies may not be an absolute requirement for 
clearance [27,66]. Despite conflicting reports regarding the importance of antibodies to the surface 
glycoproteins of HCV during acute infections such antibodies have been shown to neutralize or control 
HCV RNA levels in a number of in vivo experiments [67-69] and neutralize virus or virus-like 
particles using in vitro systems [24,54,55,62,66] and should still be considered as an important 
component of any HCV vaccine. 
5. Prophylactic Vaccines 
A list of published HCV prophylactic vaccine studies in chimpanzees is shown in Table 1; these 
studies can roughly be divided into vaccines designed to induce T-cell responses, targeting non-
structural proteins, or those primarily designed to induce neutralizing antibody responses, targeting the 
envelope region of the virus. The majority of vaccine studies have used homologous virus to 
challenge, i.e. the same genotype as that represented by the vaccine. In some publications the 
challenge virus is referred to as “heterologous” where a different variant of the same genotype has 
been used with approximately 7% diversity from the vaccine-based sequence. For consistency with 
terms of genetic diversity, in Table 1 “heterologous” has only been used to describe the challenge virus 
when a different genotype was used. This occurred in only one vaccine study performed by Folgori et 
al. [26] where the vaccine used genotype 1a sequences and the challenge was performed with a 
genotype 1b virus. Youn et al. [70] used a number of different genotypes to reinfect chimpanzees that 
had recovered from the primary challenge following vaccination. However, as these challenges 
followed clearance of a primary infection after vaccination, the extent to which the post-vaccine 
primary infection contributed to control or protection from the heterologous challenge can not be 
differentiated from the effect of the vaccine. 
The majority of vaccine studies have used small numbers of chimpanzees (between one and six 
animals per study); however, important information can be gained from each one of these studies. Of 
particular importance is the fact that every prophylactic vaccine study published has successfully 
induced HCV-specific immune responses and has also led to modification of HCV replication soon 
after challenge, indicating that the vaccines have been effective at priming antibody or T-cell 
responses that can inhibit viral replication. However, despite this initial control persistent infections 
have developed in a number of the vaccinated chimpanzees. The persistence in some cases has been 
associated with immune escape in CD4+ [25] or CD8+ [26] T-cells and with higher viral mutation 
rates [71], suggesting that in cases where the immune response cannot rapidly clear the virus there 
remains an environment for selective pressure. Interestingly, the vaccines that seem to have had the 
greatest success at protection or leading to resolved infections have included all or part of the HCV 
envelope region inducing primarily either neutralizing antibody [72-74] or E1E2 T-cell responses 
[70,75]. These data suggest that neutralizing antibodies can play a role in protection but also that this 
region may contain T-cell epitopes that are important for clearance.  
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Table 1. Prophylactic HCV Vaccine Studies in Chimpanzees. 
Vaccine 
(Genotype sequence used) 
(Number of animals vaccinated) 
Immunogenicity Challenge 
Inoculum* 
Dose (CID50§) 
Outcome Ref. 
Recombinant gpE1/gpE2 in Oil/water 
adjuvants 
(Genotype 1a) 
(N=21) 
Induced antibodies 
to E1E2 
Genotype 1a 
Homologous 
10 to 100CID50 
Protects against infection or 
chronic infection 
5 protected from infection 
14 resolved infection 
2 developed persistent infection 
[72] 
[73] 
DNA vaccine expressing E2 protein 
(Genotype 1a) 
(N=2) 
Induced antibody 
and T cell responses 
to E2. 
Genotype 1a 
Homologous 
100CID50 
Modifies infection, protects from 
chronic infection 
2 resolved infection 
[74]  
Recombinant gpE1/gpE2 in oil/water adjuvants 
(Genotype 1a) 
(N=1) 
Induced antibodies 
and cellular 
responses to E1E2 
Genotype 1a 
Homologous 
100CID50 
Delayed/modified infection 
1 developed persistent infection 
[76] 
DNA prime and protein boost (using C, gpE1, 
gpE2 and NS3) 
(Genotypes 1a (core, NS3) and 1b (core, E1E2, 
NS3)) 
(N=2) 
Induced specific T-
cell responses and 
antibody to E1 and 
E2. 
Genotype 1b 
Homologous 
25CID50 
Modifies infection, protects from 
chronic infection 
1 resolved infection 
1 developed persistent infection 
[77] 
DNA prime and Recombinant Adenovirus 
expressing core, E1,E2 and NS3 to NS5B 
(Genotype 1b) 
(N=6) 
Induced specific T-
cell responses and 
anti-E2 antibody 
(neutralizing) 
Genotype 1b 
Homologous 
100CID50 
Modifies infection, protects from 
chronic infection 
1 protected from infection 
1 resolved infection 
4 developed persistent infection 
[78] 
 
DNA prime and Recombinant VV expressing 
NS3,NS5A,NS5B 
(Genotype 1a) 
(N=1) 
Induced specific T-
cell responses 
Genotype 1a 
Homologous 
100CID50 
Modifies infection 
1 developed persistent infection 
[25] 
DNA prime and Recombinant Adenovirus 
expressing NS3 to NS5B 
(Genotype 1b) 
(N=5) 
Induced specific T-
cell responses 
Genotype 1a 
Heterologous 
100CID50 
Modifies infection, protects from 
chronic infection 
4 resolved infection 
1 developed persistent infection 
[26] 
DNA prime and rMVA boost (using C, gpE1, 
gpE2 and NS3) 
(Genotype 1b) 
(N=4) 
Induced specific T-
cell responses and 
antibody to E1 and 
E2. 
Genotype 1b 
Homologous 
25CID50 
Modifies infection, protects from 
chronic infection 
1 resolved infection 
3 developed persistent infection 
[79] 
Recombinant VLPs containing C, E1 and E2 
(Genotype 1b) 
(N=4) 
Induced specific T-
cell responses. No 
detectable anti-
E1E2 response. 
Genotype 1b 
Homologous 
100CID50 
Modifies infection, protects from 
chronic infection 
4 resolved infection 
[75] 
Recombinant VV core, E1, E2, p7, NS2 and 
NS3 
(Genotype 1b) 
(N=4) 
Induced specific T-
cell responses. 
Weak anti-E1E2 
response. 
Genotype 1b 
Homologous 
2.5 and 
24CID50† 
Modifies infection, protects from 
chronic infection 
4 resolved infection 
[70] 
DNA prime and Recombinant Adenovirus 
expressing NS3,NS5A,NS5B 
(Genotype 1a) 
(N=2) 
Induced specific T-
cell responses 
Genotype 1a 
Homologous 
100CID50 
Modifies infection or protects 
from chronic infection 
1 resolved infection 
1 developed persistent infection 
[71] 
* Homologous and heterologous refer to the same or different genotype, respectively;   
§ CID50=50% chimpanzee infectious doses; † Animals erroneously received 2.5CID50 which did 
not lead to infection in control animals. Animals were then challenged with 24CID50. 
 
A major question surrounding HCV prophylactic vaccines is what should be the expected outcome 
following exposure in vaccinated individuals? Is sterilizing immunity a realistic goal or should rapid 
control of viral replication followed by clearance be an acceptable endpoint? Given our current 
knowledge of viral kinetics in secondary infections and results of a relatively large number of different 
vaccine studies in chimpanzees it appears that sterilizing immunity may not be achievable or 
guaranteed in 100% of cases. It has been shown that a number of well-established, highly important, Viruses 2009, 1                                       
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licensed vaccines do not confer sterilizing immunity (e.g. measles [80], influenza [81], polio [82]) in 
that viral replication can be shown in vaccinees following exposure using cell culture or antigen 
studies. However, it has been clearly demonstrated that these vaccines induce immune responses that 
protect against illness, reduce the level of viral replication and have been enormously successful at 
controlling disease. The current methods that have been developed for detecting HCV in plasma are 
PCR-based assays that can detect very low amounts of virus, such as the transcription-mediated 
nucleic acid amplification assay (TMA) which can detect as few as 50 HCV RNA copies/mL [83]. 
These are far more sensitive than assays that were in place many years ago when most of the current 
vaccines for viral infections were developed. For example, when the hepatitis A (HAV) and hepatitis B 
(HBV) vaccines were licensed PCR testing had either not been developed or was in its infancy. In the 
pivotal clinical trials performed for the two main HAV vaccines currently on the market (Havrix® and 
VAQTA®) a case was defined by the presence of typical signs and symptoms, a diagnostic increase in 
IgM antibody to hepatitis A, and elevated serum concentrations of alanine aminotransferase [84,85]. 
HBV vaccines have been commercially available since 1982, well before PCR techniques were 
developed, with vaccine failures defined as the presence of surface antigen or core antibody or the 
absence of surface antibody [86]. Only recently in clinical trials for Human Papilloma virus (HPV) 
vaccines was PCR technology used to detect viral DNA but persistent HPV-16 infection was defined 
as the detection of HPV-16 DNA in samples obtained at two or more visits, with test samples obtained 
at enrollment, one month after the third vaccination, and every six months thereafter [87]. Therefore, 
in this most modern of vaccines designed to protect against a persistent viral infection transient viral 
replication was either acceptable or would have been missed. Similarly, preventing chronic infection 
with respect to HCV in the absence of sterilizing immunity may be an acceptable goal for a vaccine as 
in humans it is chronic persistence of the virus that is mainly associated with pathogenesis and the 
development of serious liver conditions [88,89]. 
Antibody Based Prophylactic Vaccines: The most comprehensive prophylactic vaccine studies have 
been performed by the Chiron/Novartis group led by Michael Houghton. Using an oil/water 
adjuvanted HCV envelope gpE1/gpE2 vaccine designed to induce neutralizing antibodies they have 
been able to compare the outcome of infection in a relatively large number of vaccinated chimpanzees 
(n=21) versus untreated controls (n=24) [72,73]. This recombinant vaccine was shown to elicit specific 
antibody and T cell responses. In animals with high anti-envelope antibody titers apparently sterilizing 
immunity was achieved, as assessed by RT-PCR, but even in vaccinated animals where virus could be 
detected by RT-PCR in the plasma post challenge the outcome of infection in vaccinees was more 
likely to result in clearance than persistence compared with untreated controls (p=0.002). Similarly, 
chimpanzee studies by Forns et al. [74] using a DNA plasmid to induce anti-E1E2 immune responses 
found modified infection and rapid clearance of HCV associated with high anti-envelope antibody 
titers. Furthermore, Puig et al. [76] showed that coupling a vaccine-induced anti-E1E2 antibody 
response, using recombinant gpE1/gpE2, with natural immunity resulting from clearance of the 
primary infection in a chimpanzee led to a subclinical infection upon rechallenge [76]. These data 
provide the most promising indications that antibodies to gpE1/gpE2, possibly coupled with T cell 
responses, can be protective by preventing or modifying HCV infection such that the virus can be 
cleared. However, although a number of neutralizing epitopes in E1 and E2 have been identified  Viruses 2009, 1                                       
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[28-30,55] and neutralizing antibodies have been raised in vaccinated chimpanzees [76,78,90] whether 
sterilizing immunity is consistently possible or what levels of in vivo titers are required to achieve 
either sterilizing immunity or successful modification of infection such that clearance is always 
achieved is still unknown. 
The greatest challenge to neutralizing antibody-based vaccines when using a monotypic antigen for 
immunization is the generation of heterologous protection that can neutralize more than one genotype 
of HCV. Zhang et al. [90] recently showed that heterologous neutralizing ability is present in plasma 
from chimpanzees vaccinated with monotypic antigen but cross-neutralization could only be revealed 
when interfering antibodies specific to an epitope adjacent to a conserved neutralizing epitope in E2 
were blocked such that the antibodies specific to the conserved region could be functional [90,91]. 
These findings have significant implications for development of an E1E2-based vaccine suggesting 
that the removal of specific immunogenic but non-neutralizing regions from a recombinant E1E2 
vaccine could lead to the induction of a cross-neutralizing immune response. Further studies of this 
type need to be performed analyzing antibody profiles induced following vaccination and natural 
infection in order to dissect out which antibodies are effective for neutralization and which are 
immunogenic but non-neutralizing. 
T-cell based Prophylactic Vaccines: Since the demonstration that T-cells are important for clearance 
of HCV a great deal of focus has been placed on developing vaccines that will induce T-cell responses 
to HCV proteins. These types of vaccines have an advantage over vaccines that focus on inducing 
immune responses to the envelope proteins as more conserved regions of the virus can be targeted 
potentially generating a more heterologous immune response capable of protecting against a number of 
HCV genotypes. 
A number of approaches have been used to generate T-cell responses against HCV antigens in 
chimpanzee studies (Table 1); these include the use of virus-like particles and defective or attenuated 
viral vectors with or without priming of the immune system with DNA plasmids. The use of HCV 
virus-like particles produced in insect cells has proved successful at inducing effective HCV-specific 
immune responses, although interestingly the responses to the structural proteins were mainly T-cell 
specific with little or no neutralizing antibody detected [75]. All of the chimpanzee vaccine studies 
published to date have been successful at inducing specific immune responses to the target antigens 
and all have resulted in modification of the HCV infection and early control of replication following 
challenge with virus. The HCV-specific T-cells induced have been shown to produce IFN-γ and in 
many cases additional cytokines such as IL-2 and IL-4. However, eliciting broad CD4+ and/or CD8+ 
T-cell responses has not always prevented persistent infections in the animals studied. In some cases 
the development of persistent infections have been associated with lower immune responses compared 
to other vaccinees [26,77] or higher levels of viral mutation rates and immune escape [25,26,71]. 
Although it is difficult to quantitatively compare T-cell assays between different groups and 
laboratories the vaccine studies performed using the chimpanzee model seem to have induced more 
robust immune responses than those routinely detected in recovered patients or chimpanzees 
suggesting the quality of the immune response is more important than a quantitatively strong immune 
response for rapid clearance of the virus. These findings emphasize the importance of the chimpanzee 
model for testing the efficacy of a vaccine-induced response before proceeding to clinical trials. In the Viruses 2009, 1                                       
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next generation of vaccine studies detailed analyses need to be performed of T-cell phenotypes 
induced and functional markers of protection such as homing profiles, central and effector memory 
phenotypes, T helper function and proliferation using markers such as CCR7, CD28, CD62L and 
CD45RA (reviewed [92]). It is possible that in cases where T-cell vaccines fail to clear the virus the 
induced HCV-specific cells are only secreting a single cytokine, such as IFN-γ, while it is necessary to 
induce polyfunctional cells that secrete multiple cytokines, such as IL-2 and TNF-α, as has been 
achieved with HIV vaccines [93]. These types of studies require large numbers of cells but are 
necessary before vaccines move into clinical trials involving any populations at risk for infection  
with HCV. 
The types of viral vectors used for HCV T-cell vaccines are common to a number of strategies used 
for other vaccine targets such as HIV and include adenovirus [26,71,78] and vaccinia virus 
[25,70,77,79] vectors. Transferring these viral vectors to human clinical trials may be challenging due 
to pre-existing immunity or adverse side effects. Adenovirus vector modifications have been 
extensively explored in the vaccine field and include the use of alternative serotypes and genetic 
modifications [26,94]. In addition, a highly attenuated strain of vaccinia virus (Modified Vaccinia 
Ankara, MVA) has been developed which has proved to be immunogenic and as effective at eliciting 
immune responses as wild type virus [95,96]. The studies in chimpanzees to date have mainly been 
performed in order to establish whether a vaccine-induced T-cell response can be effective at 
modifying HCV infection and replicating the type of viral kinetics seen in recovered/rechallenged 
animals. A greater number of vector and delivery systems have been explored in animal systems other 
than the chimpanzee model and have been successful at inducing HCV-specific immune responses. 
Replication-defective alphavirus particles have been used in mice to induce NS3-specific cytotoxic  
T-cell responses [97] or in combination with Th1-adjuvanted proteins to induce neutralizing antibodies 
as well as broad CD4+ and CD8+ T-cell responses to non-structural proteins [98]. Alphaviruses are 
attractive as gene delivery systems due to high levels of foreign gene expression [99]; dsRNA 
intermediates, which can stimulate the innate immune system [100]; and the potential for cross 
presentation of antigen due to cytopathic effect. However, there are concerns regarding safety of 
Venezuelan equine encephalitis virus replicons and the replication levels and immunogenicity of 
Sindbis virus in humans [101]. An adenovirus vector-based minigene vaccine encompassing four 
domains of the NS3, NS4 and NS5B proteins that contain multiple class I/II restricted epitopes also 
induced strong and broad HCV-specific T-cell responses in HLA-A2 transgenic mice [102] and may 
prove promising as a tool for inducing cross-reactive responses. However, as challenge experiments 
have not been performed with these newer systems to determine efficacy caution needs to be taken in 
assessing potential success following scale-up to chimpanzees or humans in the clinical setting.  
6. Therapeutic Vaccines 
Great progress has been made in the therapy for HCV but the current standard of care for chronic 
infections still remains a combination of pegylated IFN-α and Ribavirin for 6-12 months. Previously 
clinical results showed an almost 100% sustained viral response rate in patients when treatment is 
initiated early (89 days) after infection [103] as compared with 50% of cases in the chronic phase [7]. 
However despite promising results for the treatment of new infections there still remains the problem Viruses 2009, 1                                       
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of treating the ~170 million chronically infected patients worldwide, many of whom have not 
responded to IFN/Ribavirin treatment in the past. With the advances in cell culture systems to study 
HCV replication [56,57,104,105] there has been a great deal of focus on the development of drugs to 
specifically inhibit viral enzymes such as the protease; helicase; and RNA-dependent RNA 
polymerase. In addition there is a role for therapeutic strategies to enhance HCV-specific immune 
responses that may be used alone or in conjunction with existing or new antiviral therapies. 
A number of diverse therapeutic vaccine trails have been performed; these are listed in Table 2. 
Unlike prophylactic vaccines these have been carried out in HCV infected patients or healthy 
volunteers in a clinical setting. The approach of therapeutic vaccines has been similar to prophylactic 
vaccines in that the major goal has been to enhance HCV-specific T-cell responses although 
enhancement of envelope antibody responses has also been included in a number of studies. The 
strategies have included using recombinant proteins (core or E1) adjuvanted with ISCOMATRIX or 
alum. ISCOMATRIX is an adjuvant that forms a cage-like structure resulting in the induction of 
antibody and T-cell responses. Other strategies have used peptide vaccines; DNA vaccines, MVA 
vectors, and heat-inactivated antigens from HCV-infected donors. The current therapeutic vaccine 
trails to date have not succeeded in clearing HCV infections or achieving sustained reductions in viral 
titers. However, the studies have all successfully stimulated HCV-specific immune responses with 
transient reductions in viral RNA titers [106-108] and possible stabilization or improvement in liver 
histology or liver enzymes [109-111] in subsets of patients. Recently, the therapeutic peptide vaccine 
IC41 was added to pegylated IFN/Ribavirin treatment [112] in an attempt to decrease the relapse rate 
in patients receiving standard therapy. Although the IC41 vaccine did not prevent HCV-RNA relapse, 
specific T-cell responses were induced and were associated with lower relapse rates. 
In addition to human therapeutic vaccine trials some in vitro studies have been performed using 
peripheral blood mononuclear cells from HCV infected patients [113,114]. One study used synthetic 
self-adjuvanting lipopeptides containing a CD4+ helper epitope and an NS5B epitope from HCV 
together with a ligand for Toll-like receptor 2 on dendritic cells (DCs) [113] for DC-based 
immunotherapy of HCV infection. The lipopeptides were able to activate monocyte-derived DCs from 
both healthy and HCV infected patients, the pulsed DCs were also able to activate autologous CD8+ 
T-cells from an HCV patient. A second study used modified adenovirus recombinants expressing core 
and NS3 of HCV [114]. The recombinant was able to activate and expand HCV-specific T-cells from 
HCV-infected donors in vitro. These strategies have yet to be tested in patients for effects on HCV 
viral titers but both have promising implications for immunotherapy. 
Some strategies used for therapeutic vaccines (e.g. peptide or DNA vaccination) may not be as 
effective in naïve patients for inducing a de novo immune response compared to persistently infected 
patients where the immune system has already been primed by the natural infection. However, the 
same or similar viral vectors, such as MVA, could in principle be used for both types of vaccination 
strategies. Approaches such as the use of inactivated HCV antigens derived from HCV-infected donors 
may be considered too high a risk for use in healthy individuals as a prophylactic vaccine although if 
this proved effective at reducing HCV titers or clearing the virus recombinant forms of the proteins 
could be considered for future development. As more information is gained about possible immune 
dysfunction that may occur in persistently infected patients, therapeutic vaccines may need to be 
tailored to include specialized immunostimulatory molecules such as ligands for Toll-like receptors or Viruses 2009, 1                                       
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vectors that secrete cytokines shown to be poorly expressed by T-cells from chronically   
infected patients. 
Table 2. HCV Immunotherapeutic Vaccine Studies. 
Vaccine 
(Genotype sequence used) 
Patient HCV 
Genotype 
Immunogenicity Outcome  Ref. 
Alum-adjuvanted recombinant 
gpE1 protein 
(Genotype 1b) 
*Genotype 1a 
  Genotype 1b 
Antibody and T-cell responses in 
some healthy volunteers. 
Boosts humoral and cellular 
responses in a subset of patients 
May ameliorate hepatitis  [109] 
[115] 
[116] 
Peptide vaccine targeting E1, 
E2, NS3 and NS5A. 
(Genotype 1b) 
Genotype 1b  Boosted peptide-specific T-cell 
and antibody responses. 
Decreased ALT levels 
and HCV RNA levels in a 
subset of patients. 
[106] 
DNA vaccine (CIGB-230) 
expressing core, E1, E2 plus 
recombinant core protein 
(Genotype 1b) 
Genotype 1b  Boosted neutralizing antibody 
responses and T-cell responses in 
patients. 
May ameliorate hepatitis  [110] 
Synthetic peptide vaccine 
(core, NS3, NS4) IC41 with or 
without poly-L-arginine. 
Genotype 1 
Genotype 1 
Genotype 3 
Genotype 4 
Boosted T-cell responses in 
patients. 
Transient decline (>1-
log) in HCV serum RNA 
titers in a subset of 
patients. 
[107] 
V-5 Immunitor – heat-
inactivated HCV antigens from 
HCV-infected donors 
administered orally in tablet 
form. (Genotype not defined) 
Genotype not 
defined 
Not measured.  Decreased liver enzyme 
levels. May improve 
HCV-associated clinical 
symptoms. 
[111] 
ICOMATRIX-adjuvanted 
recombinant core protein 
(Genotype 1a) 
Healthy 
patients used.  
Induced HCV-specific immune 
responses and CD+ T-cell 
responses in a subset of patients. 
Clinical trial in healthy 
adults, no HCV infected 
patients tested. 
[117] 
[118] 
[119] 
MVA expressing NS3, NS4 
and NS5B proteins (Transgene 
TG4040).  
(Genotype 1b) 
Genotype not 
defined 
Boosted HCV-specific immune 
responses 
Transient decrease in 
viral load in a subset of 
patients. 
[108] 
[120] 
[121] 
* Cohort consisted of healthy volunteers, and recovered patients in addition to HCV infected 
patients. Genotype refers to viral genotype in the HCV infected patients only. 
The enhancement of HCV-specific immune responses in chronically infected patients is 
encouraging but further investigation and follow-up of existing clinical trials is required to determine 
if changes in the observed parameters in treated patients are sustained; if there is immune escape of the 
circulating virus from the boosted immune response and whether this may contribute to the transient 
reductions in virus titers; and what impact these strategies may have on patient outcome if combined 
with current or newly developed antiviral therapy. 
7. Conclusions 
In conclusion, the prospects for HCV vaccines are better today than they have ever been. This is 
partly due to overall advances in vaccine technology and methods to analyze and characterize immune 
responses but it is also due to advances in our specific understanding of natural HCV immunity, HCV 
replication and kinetics and the development of new tools to test antibody immune responses such as Viruses 2009, 1                                       
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pseudotype particles and cell culture grown virus. However, there is still a great deal of missing 
information. We still do not know which types of immune responses correlate with protection or 
clearance of HCV during natural infection or the types of immune responses that are present during 
chronic infections that seem to exert only partial control of HCV. New vaccine studies also need to 
include higher level immunological analyses examining multifunctional activities of T-cells and T-cell 
phenotypes. It is still too early to assess how cross protective any vaccine candidate may be, mainly 
due to the difficulties of challenging large numbers of chimpanzees with multiple heterologous 
genotypes. Our current understanding from chimpanzee rechallenge studies and human exposure 
studies certainly indicates that natural cross protective immunity is present following a single genotype 
infection, suggesting that a multivalent vaccine tailored to all six genotypes would not be necessary. 
The development of a small animal model that is immunocompetent would advance the field 
enormously although care should always be taken in extrapolating data to humans as many immune 
response studies in mice have not translated well to humans and primates. We also need to investigate 
the effects of vaccine-induced immune responses on immune escape and possible persistence of HCV; 
this applies to both prophylactic and therapeutic vaccines. 
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